

Session 12:

A Moderated Discussion of Current Events and Difficult Cases



Program, Presentation Slides: http://alternativeprograms.org/schedule



Objectives

- Share ideas and techniques utilized by different programs related to these situations or issues on various topics
- Discuss Difficult Cases and Current Events that effect alternative Programs.



Program, Presentation Slides: http://alternativeprograms.org/schedule



Issues Addressed by most ATD and Board Programs

- Medication Assisted Treatment
- Prescription Medication Use
- Program Referrals
- Professional Sexual Misconduct
- Cultural and Religious Sensitivity
- Mental Health Problems



Program, Presentation Slides: http://alternativeprograms.org/schedule



Medication Assisted Treatment For Opioids Use Disorder

(MOUD) is the use of medications in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders.





Common MAT Medications

FDA has approved several different medications to treat Opioid Use Disorder/Addiction.

- Methadone (agonist) used in MAT for opioid treatment can only be dispensed through a SAMHSA-certified Opioid Treatment Program.
- Buprenorphine with and without naloxone Suboxone®, Subutex® (partial agonist) can be prescribed by HCP with a DEA number and a minimum of an eight-hour course.
- Naltrexone Vivitrol® (antagonist) needs no special waiver or certification.



Program, Presentation Slides: http://alternativeprograms.org/schedule



MOUD-Upside

The ultimate goal of MOUD is full recovery, the ability to live a self-directed life. This treatment approach has been shown to:

- •Improve patient survival
- Increase retention in treatment
- Decrease illicit opiate use and other criminal activity
- Increase patients' ability to gain and maintain employment





MAT - The Downside

- Harm reduction model.
- •Doesn't allow the brain to heal- research is ongoing.
- •Buprenorphine is highly diverted, mis-used and often self-regulated and used to supplement drug use, not replace it.
- Very difficult to wean off in the outpatient environment
- Potential for cognitive impairment- especially when selfregulated.



Program, Presentation Slides: http://alternativeprograms.org/schedule



ADA DISCRIMINATION

Per DOJ:

Indiana Nursing Board is a Public Entity (Regulatory/Licensing Authority). A.D.A. Title II prohibits disability discrimination by Public Entities. Opioid Use Disorder is an A.D.A protected disability when the person is:

- ✓ "successfully rehabilitated"
- √ "no illegal drug use"

Nursing Board: abstinence was required; mandatory taper off Suboxone/Methadone

D.O.J.: an abstinence program with a total ban on M.A.T. is A.D.A. discriminatory





Discussion

- 1. Does your program support the use of medications for opioid use disorders (MOUD) for participants with opioid use disorder?
- 2. Is Buprenorphine treatment problematic in the monitored healthcare professional?
- 3. How concerned are you that ADA protections for individuals with OUD may interfere with qualified medical decision-making in selecting the most appropriate treatment for the monitored health professional?



Program, Presentation Slides: http://alternativeprograms.org/schedule



Prescription Medication

- Does your board or program allow participants to take prescribed medications (ex. ADHD, Post-Operative, etc.)
- If so, do you require additional testing?





REFERRALS

- Did you notice a decrease in the number of referrals since 2020?
- Has your program or board come up with new ways to encourage referrals?



Program, Presentation Slides: http://alternativeprograms.org/schedule



Professional Sexual Misconduct

- Does your program or board monitor professional sexual misconduct cases?
- If yes, what is your process?
- If no, why not?





Cultural and Religious Sensitivity

- How does your state program address cultural and religious sensitivity?
- a. Toxicology Screens
- b. Religious Holidays
- c. Overcome Language Barriers



Program, Presentation Slides: http://alternativeprograms.org/schedule



Overall Monitoring Compliance

Case 1:

- Male nurse, early 40's diagnosed with Alcohol Use Disorder, Moderate, and Major Depressive Disorder, Severe
- Toxicology: Breathalyzer, UDS, Peth
- Missed (2) Breathalyzer tests, resulting in PETH
- Positive PETH 224ng/ml
- While in treatment, participant disclosed consuming half
 750ml of gin a day under monitoring >4 months





Overall Monitoring Compliance

- Case 2
- RN, diagnosed with Opioid Use Disorder, Moderate, and Major Depressive Disorder, Severe. History of Chronic Pain and Chronic Relapses
- Toxicology: UDS, Hair
- Request to use Buprenorphine product (Suboxone)



Program, Presentation Slides: http://alternativeprograms.org/schedule





2024 Annual Education Conference

May 14 - 17, 2024

Marriott Sanibel Harbor Resort

Fort Myers, Florida

http://AlternativePrograms.org/Conference